CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...